drugset / Trial / NCT00658723

The Fibrin Patch Soft Tissue Study

NCT00658723

Phase 2 Completed 141 enrolled Ethicon, Inc. OMRIX Biopharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.

Timeline

Start
2008-03
Primary completion
2009-04
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fibrinogen Concentrate Human Protein / enzyme biologic Topical
Subject Human Thrombin Protein / enzyme biologic Topical